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Abstract
Background:  A major marketing technique used by pharmaceutical companies is direct-to-
physician marketing. This form of marketing frequently employs promotional marketing brochures,
based on clinical research, which may influence how a physician prescribes medicines. This study's
objective was to investigate whether or not the information in promotional brochures presented
to physicians by pharmaceutical representatives is accurate, consistent, and valid with respect to
the actual studies upon which the promotional brochures are based.
Methods: Physicians in five clinics were asked to consecutively collect pharmaceutical promotional
brochures and to send them all to a centralized location. The brochures for any class of medication
were collected on a continuous basis until 20 distinct promotional brochures were received by a
central location. Once the brochure was received, the corresponding original study was obtained.
Two blinded reviewers performed an evidence-based review of the article, comparing data that was
printed on the brochure to what was found in the original study.
Results: Among the 20 studies, 75% of the studies were found to be valid, 80% were funded by
the pharmaceutical company, 60% of the studies and the corresponding brochures presented
patient-oriented outcomes, and 40% were compared to another treatment regimen. Of the 19
brochures that presented the data as graphs, 4 brochures presented a relative risk reduction while
only 1 brochure presented an absolute risk reduction. 15% of the promotional marketing
brochures presented data that was different from what was in the original published study.
Conclusion: Given the present findings, physicians should be cautious about drawing conclusions
regarding a medication based on the marketing brochures provided by pharmaceutical companies.
Background
The pharmaceutical industry spent over $11 billion in
pharmaceutical marketing, excluding medication sam-
ples, in 2004, with more than $7 billion directed to clini-
cians [1]. This creates the potential for an ethical dilemma
because such marketing may influence physician prescrib-
ing behavior without necessarily benefiting the patient [2-
6]. Such marketing also creates the potential for inappro-
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priate prescribing practices, which contribute to escalating
national health care costs[7].
There is an ongoing debate on the effects of pharmaceuti-
cal marketing on health care delivery. For example, while
diuretic and beta-blocker medications are considered the
first line antihypertensive therapies (both medications
being relatively inexpensive and available in generic
forms), extensive marketing campaigns by pharmaceuti-
cal companies to promote calcium channel blockers
(CCBs) resulted in the largest growth in revenues for this
class of anti-hypertension drugs during the 1990s [8]. The
percentage of CCB advertisements increased from 4.6% in
1986 to 26.9% in 1996, while advertisements for beta-
blockers and diuretics decreased from 12.4% to 0% and
from 4.2% to 0%, respectively, during the same time
period [9]. It was also noted that CCBs accounted for 38%
of antihypertensive prescriptions written in 1995, while
diuretics and beta-blockers combined accounted for only
19% [8]. This, in essence, affected the standard of care in
the management of hypertension, [10] even though CCBs
may increase the risk of fatal and nonfatal myocardial inf-
arction by 18% [11]. Lack of compliance with antihyper-
tensive guidelines, by using second-line medications over
first-line medications, was associated with potential
increases in health care expenditures in the range of $2.6
billion to $3.2 billion in 1996 [7].
Direct-to-physician (DTP) marketing is one important
facet of the promotion of pharmaceuticals. DTP includes
verbal in-office presentations which are usually accompa-
nied by promotional advertising brochures, free medica-
tion samples, and possibly gifts such as meals or other
promotional items. These in-office presentations by phar-
maceutical representatives (PRs) are an important
method of promotion for pharmaceutical companies.
Their impact is undeniable, as PRs are most frequently
reported by physicians as their source of primary informa-
tion about new medications [12]. While direct-to con-
sumer (DTC) pharmaceutical marketing has increased
dramatically in the last decade, DTP marketing expendi-
tures remain 48% greater than for DTC marketing [1].
There is concern about the influence of DTP marketing on
physician prescribing practices and its consequences, such
as the physician's ethical obligation to the patient and
health care costs. Studies have repeatedly shown that
pharmaceutical promotion influences physician behavior
[3,12-14]. The more physicians are encountered by PRs,
the more likely they are to deny that they are influenced
by pharmaceutical gifts and PR interactions [15]. Some
information provided by PRs to physicians has been
found to be misleading or biased [5,16-21]. Eleven per-
cent of the verbal statements about drugs made by phar-
maceutical representatives to physicians has been found
to be inaccurate [16]. Further, a majority of journal adver-
tisements have been found to be based on studies of poor
methodological quality [22].
While studies have investigated the accuracy and influ-
ence of promotional information provided by PRs to phy-
sicians, [3,5,8,12-14,16-21] no study has assessed the
visual nature and accuracy of the data that are presented
in the promotional brochures. The accuracy and validity
of the visual displays and data presented in promotional
brochures is important because physicians who rely more
on promotional information tend to be heavier prescrib-
ers and more willing to try new medications [13,23-
28,28-31]. The objective of this study was to review the
data that is visually presented on advertisement brochures
for its accuracy, consistency, and validity.
Methods
The study was conducted in 5 family medicine clinics of
the University of North Texas Health Science Center at
Fort Worth. This study was exempt from a formal Institu-
tional Review Board review. Physicians in these clinics
were asked to collect promotional brochures that accom-
panied the PR's verbal presentation and to indicate the
one figure, table, or data that was emphasized most by the
PR. This process was used because we believed that the
data emphasized by the PR would have the greatest
impact on changing a physician's behavior. A convenience
sample of 20 distinct brochures was collected between
October 15, 2004 and December 5, 2004. Each brochure
represented one medication, outcome, and its respective
study. The sample size was determined a priori because no
studies were available to calculate an accurate sample size.
The underlying cited publication on the brochure in sup-
port of the identified promotional claim was obtained for
review. Two reviewers used a standardized form to collect
data and perform an evidence-based review of the article,
comparing data that were presented on the brochure to
those found in the underlying study. Both reviewers were
initially blinded to each other's review. The validity of an
article was determined by a series of six questions that
addressed evidence-based principles (Table 1) [32]. Valid-
ity was determined by the following method: 3 of 3 major
criteria and at least 2 of 3 minor criteria must have been
met. The disclaimers and acknowledgments of the origi-
nal study were reviewed to determine whether a pharma-
ceutical company funded the study. The outcome of
interest on the brochure was classified as patient-oriented
or disease-oriented. Patient-oriented outcomes were those
that directly affected or reflected the patient, such as mor-
tality or change in perceived symptoms such as urinary
frequency or pain. Disease-oriented outcomes were those
characteristics of the disease itself, such as change in
blood pressure measurements. The brochures' data and
their corresponding studies were reviewed to determine ifBMC Family Practice 2006, 7:13 http://www.biomedcentral.com/1471-2296/7/13
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the therapy (i.e. medication) was compared to another
therapy, placebo, or neither. The reviewers also assessed
whether relative risk changes (reduction or increase),
absolute risk changes, or both were presented on the bro-
chures, including any corresponding visual graphic. In
addition, the reviewers visually assessed how these data
were graphically presented on the brochures, such as the
use of charts, arrows, or line graphs. The statistical signifi-
cance of the outcome of interest was also assessed from
both sources. The reviewers compared the data presented
on the brochure to the data presented in the original study
to determine consistency. The results were entered into a
database and any discrepancies between the reviewers
were subsequently resolved by consensus. Data manage-
ment and statistical analysis were performed using the
SPSS software [33].
A Cohen's kappa and a prevalence-adjusted bias-adjusted
kappa (PABAK) [34] were calculated on validity assess-
ments to obtain an index of inter-rater reliability. While
under most circumstances a Cohen's kappa value would
suffice, we believe that both prevalence (the unequal dis-
tribution of "Yes" vs. "No" validity decisions between the
reviewers) and bias (from the reviewers' differing assess-
ments of the frequency of study validity) may have
yielded misleading results given our high percentage of
crude agreement. This concept has been explained in
greater detail by Feinstein and Cicchetti[35] and Byrt et al.
[34]. Thus a PABAK value may better measure agreement
between the two reviewers as it adjusts for factors (preva-
lence, bias, and agreement) present in an unbalanced 2 ×
2 agreement table.
Results
The characteristics of the 20 brochures are presented in
Table 2. The greatest number of brochures described car-
diovascular medications (45%), followed by neurological
medications (15%), genito-urinary medications (10%),
chronic pain medications (10%), diabetes mellitus medi-
cations (5%), gastrointestinal medications (5%), infec-
tions disease medications (5%), and osteoporosis
medications (5%). The reviewers rated 75% of the studies
as valid. Among the 20 underlying studies, 80% were
funded by the pharmaceutical company, 5% (1 study)
was not funded by the pharmaceutical industry, and 15%
were of unspecified funding. Sixty percent of the underly-
ing studies and their corresponding brochures presented
patient-oriented outcomes, such as mortality, pain scores,
and episodes of urinary incontinence. Only 8 of the 20
(40%) medications were compared to another treatment
regimen. Four brochures presented relative risk reduction
Table 1: Validity measures
Major criteria
1. Was the assignment of patients to treatments randomized?
2. Were all patients who entered the trial accounted for at its conclusion?
3. Were the patients analyzed in the groups to which they were randomized?
Minor criteria
1. Were patients and clinicians kept "blind" to which treatment was being received?
2. Aside from the experimental treatment, were the groups treated equally?
3. Were the groups similar at the start of the trial?
Table 2: Study measures
(N = 20)
n( % )
1. Was the study valid?
Yes 15 (75)
No 5 (25)





3. What was the study outcome?
Patient-oriented 12 (60)
Disease-oriented 8 (40)
4. What was the study therapy compared to?
Another medication or therapy 8 (40)
Placebo 10 (50)
Neither 2 (10)
5. Was a graphic* used on the brochure?
Yes 19 (95)
No 1 (5)
6. Of the brochures with graphics, how was the 
data presented?
Relative risk reduction 4 (21)
Absolute risk reduction 1 (5)
Other** 14 (74)








*Includes bar charts, line graphs, pie charts, arrows
**Includes mean change, point differences, etc
***p < 0.05BMC Family Practice 2006, 7:13 http://www.biomedcentral.com/1471-2296/7/13
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(RRR), 1 presented absolute risk reduction (ARR), and 15
presented some other statistic, such as a mean change
from baseline. A total of 95% of these brochures used
graphics to emphasize the differences between groups,
such as bar charts, arrows, or line graphs. Of these graphs,
21% presented RRR, 5% presented ARR, and 74% pre-
sented some other statistic. Only 1 brochure presented
data that were not statistically significant. Three of the
twenty (15%) brochures presented data that were differ-
ent from those published in the underlying studies.
A value of .41 was calculated for Cohen's kappa, and the
PABAK value was .60, indicating a moderate level of agree-
ment between the two reviewers [36]. The crude level of
overall agreement, unadjusted for chance, was 80%.
Discussion
Seventy five percent of the reviewed articles were consid-
ered valid. This supports findings from a previous study
that assessed whether the quality of a study was influ-
enced by sponsorship [37]. The authors found that the
majority of the studies sponsored by pharmaceutical com-
panies were of good quality. However, they also found
that published studies that were sponsored by pharma-
ceutical companies were four times more likely to have
outcomes favoring the sponsor's product than were stud-
ies that had other types of sponsors. One potential solu-
tion to reducing the skepticism resulting from industry-
funded research is to have pharmaceutical companies
improve access to their original data. Another possible
solution is for academia to have funding available to inde-
pendently conduct studies without the influence of the
pharmaceutical companies. Although pharmaceutical
companies exert control over their clinical trials, clinical
outcome studies conducted at academic health science
centers may have a role in complementing the post-mar-
keting surveillance of new drugs following FDA approval.
A large majority of the brochures presented data that were
based on underlying studies funded by the pharmaceuti-
cal company. However, a recent study by Cooper and Sch-
riger found that only 58% of the original research cited in
advertisements was sponsored by a pharmaceutical com-
pany or had a company affiliated author [38]. This devia-
tion from our results may be due to differences in
methods for ascertaining funding source and product mix
analyzed (e.g., brochures vs journal advertisements).
Alternatively, it may also reflect our study's small sample
size. There has been concern that industry-supported
manuscripts may selectively report study data that make a
medication or therapy appear more efficacious than it
actually is [39-41]. The clinician's dilemma becomes, "Are
the results from this 'valid study' truly valid?"
Although a majority of the outcomes in the reviewed stud-
ies were patient-oriented, a substantial number were not.
It is important to present data that reflects the outcome of
the patient, such as mortality, quality of life changes, and
symptom reduction. Thus, while a CCB may reduce blood
pressure just as effectively as a diuretic, patient outcomes
(e.g., mortality) may prevail in the long term [11,42].
While 95% of the brochures presented a visual graphic,
only 1 brochure presented an absolute risk reduction and
4 brochures presented relative risk reductions. This "fram-
ing effect" may mislead physicians to conclude that a large
difference in outcome occurs with the use of the pro-
moted medication or therapy [32]. Moreover, as the con-
sistency of outcomes was being assessed in the underlying
study and its subsequent promotional brochure, the
reviewers noted that the overwhelming majority of data
selected for the brochure were based on a desired visual
impact. Although it was not a part of this study's objec-
tives, it appeared that pharmaceutical companies often
selected the outcome with the greatest relative risk reduc-
tion or percent-change from baseline in lieu of more clin-
ically important findings in the original manuscript. This
is an area for further research and scrutiny.
A minority of the studies (eight of 20) compared the med-
ication to another medication or treatment strategy. When
a medication has already been approved by the Food and
Drug Administration, subsequent studies that compare
that medication to placebo have limited value to practic-
ing physicians, as efficacy has already been established. It
is of more value to physicians for studies to compare new
medications to generic and inexpensive medications that
are currently used in practice to determine if a change in
disease management is indicated.
Although three of the 20 brochures presented data that
were different from the original study, the differences
were small and most likely would not have affected the
clinician's prescribing behavior.
This study had several limitations. Only two blinded
reviewers were available and any discrepancies were
resolved by consensus rather than adjudication by a third
reviewer. The method in which the reviewers deemed the
underlying studies valid has not been validated in previ-
ous studies. The sample size may have been too small to
detect clinically important findings. Because brochures
were collected only in selected family medicine clinics in
one city, these findings may not be generalized to other
specialties, settings (i.e. hospital), or geographic regions.
Only brochures were studied, therefore these findings
may not be generalized to other types of promotional
products or advertisements, such as journal advertise-
ments. We believe that successful drug marketing to phy-BMC Family Practice 2006, 7:13 http://www.biomedcentral.com/1471-2296/7/13
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sicians entails more than simply presenting a brochure to
the physician and this study only assessed one aspect of
drug marketing tactics. There may be seasonal variations
in drug marketing that further limit generalizability,
although this may have been mitigated to some degree by
the wide range of drugs included in the study.
Conclusion
Given the present findings, physicians should be cautious
about drawing conclusions based on data presented on
brochures provided by pharmaceutical companies. It
would be prudent for physicians to review the original
study prior to changing prescribing behavior based on
promotional brochures only. Further, physicians should
be familiar with and utilize the principles of evidence-
based medicine in assessing the validity of published
studies. As our study was a descriptive cross-sectional
study with the primary purpose of using a semi-objective
methodology to review pharmaceutical brochures and
their corresponding published studies, future research
needs to determine not only how the promotional bro-
chure plays in overall DTP marketing and how pharma-
ceutical brochures affect physician prescribing behaviors,
but also if patient outcomes are associated with such
changes.
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